Next Article in Journal
Depression Symptom Patterns and Social Correlates among Chinese Americans
Previous Article in Journal
Blood Flow and Continuous EEG Changes during Symptomatic Plateau Waves
Previous Article in Special Issue
Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center
Editorial published on 26 December 2019, see Brain Sci. 2020, 10(1), 15.
Open AccessReview

Glioblastoma under Siege: An Overview of Current Therapeutic Strategies

Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy
Author to whom correspondence should be addressed.
Brain Sci. 2018, 8(1), 15;
Received: 22 November 2017 / Revised: 8 January 2018 / Accepted: 12 January 2018 / Published: 16 January 2018
(This article belongs to the Special Issue Advances in Adult and Pediatric Brain Tumor Management)
Glioblastoma is known to be one of the most lethal and untreatable human tumors. Surgery and radiotherapy in combination with classical alkylating agents such as temozolomide offer little hope to escape a poor prognosis. For these reasons, enormous efforts are currently devoted to refine in vivo and in vitro models with the specific goal of finding new molecular aberrant pathways, suitable to be targeted by a variety of therapeutic approaches, including novel pharmaceutical formulations and immunotherapy strategies. In this review, we will first discuss current molecular classification based on genomic and transcriptomic criteria. Also, the state of the art in current clinical practice for glioblastoma therapy in the light of the recent molecular classification, together with ongoing phases II and III clinical trials, will be described. Finally, new pharmaceutical formulations such as nanoparticles and viral vectors, together with new strategies entailing the use of monoclonal antibodies, vaccines and immunotherapy agents, such as checkpoint inhibitors, will also be discussed. View Full-Text
Keywords: monoclonal antibodies; alkylating agents; nanoparticles; immunotherapy monoclonal antibodies; alkylating agents; nanoparticles; immunotherapy
MDPI and ACS Style

Paolillo, M.; Boselli, C.; Schinelli, S. Glioblastoma under Siege: An Overview of Current Therapeutic Strategies. Brain Sci. 2018, 8, 15.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop